‘Stratus' COVID variant spreads in US: All you need to know
So far, data suggest this variant does not cause more severe illness or higher mortality compared to other circulating strains.
The CDC highlighted that states including Alabama, Alaska, California, Delaware, Florida, Hawaii, Kentucky, Louisiana, and Texas are experiencing high or very high case levels.
Other states such as Connecticut, Georgia, Indiana, Maryland, Michigan, Minnesota, Mississippi, Missouri, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Utah, Virginia, Washington, and Wisconsin are also seeing a rise in cases linked to this variant.
Also Read | New COVID variant bizarre symptoms: What treatments are available and how you can protect yourself
All you need to know about Variant XFG
XFG is a recombinant strain formed by combining two earlier variants: F.7 and LP.8.1.2, the latter now the second most common strain in the US.
Scientists suggest it carries mutations that may help it evade the immune system better, though this does not mean it spreads faster.
Originally identified in Southeast Asia in January, XFG accounted for nearly 0% of US cases in March but grew to 2% in April, 6% in May, and about 14% by late June, according to the Centers for Disease Control and Prevention (CDC).
A similar rise has been seen globally, with the World Health Organization (WHO) reporting XFG made up 7.4% of cases in early May, increasing to 22.7% by the end of June across 38 countries.
In a late June report, WHO placed XFG on its watchlist but assessed the additional public health risk as "low" worldwide. It also stated that current COVID-19 vaccines are "expected to remain effective to this variant against symptomatic and severe disease."
Classified as a SARS-CoV-2 variant under monitoring (VUM), XFG is spreading globally, but based on available evidence, WHO considers its additional public health threat to be low.
What are the symptoms?
The CDC continues to list common COVID symptoms such as:
Fever or chills
Cough
Fatigue
Sore throat
Loss of taste or smell
Congestion
Muscle aches
Shortness of breath
Headache
Nausea or vomiting
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scroll.in
38 minutes ago
- Scroll.in
Heart and kidney diseases, cancer: What else can GLP-1 drugs treat in addition to obesity?
Research into the sugar-lowering powers of incretin hormones led to the discovery of GLP-1 drugs [like Ozempic and Mounjaro]. The added bonus of weight loss was serendipity. There seem to be many happy side effects of GLP-1 drugs. Of course, many of them are not because of the drugs themselves but because of weight loss. When you lose weight – whether through diet and exercise, bariatric surgery, or GLP-1 drugs – your knee pain and inflammation will reduce, heart health will improve, and so on. Yet it seems that GLP-1 drugs are directly improving health outcomes as well, apart from the benefits that accrue by reducing blood sugar and hunger. Dr Daniel Drucker, one of the scientists who discovered the GLP1 hormone, conducted an experiment on mice with systemic inflammation. When treated with GLP-1 drugs, the inflammation decreased. However, if the drug was blocked from reaching the brain, the inflammation did not reduce. This suggests that the brain plays a critical role in inflammation, and that reducing it may be directly mediated through the brain and not just indirectly due to weight loss. GLP-1 receptors – the switches activated by the drug – are found in the heart, liver, kidneys, pancreas, stomach, intestines and brain. As with many hormones, GLP-1's effects may not be limited to hunger and satiety alone but may also have multiple other functions. The full range of benefits these drugs can have in treating various diseases is still being discovered. In October 2018, Novo Nordisk, the company that holds the patent for semaglutide, began a trial to study the impact of the drug on the cardiovascular health of people who had heart disease and were overweight or obese but did not have diabetes. They enrolled over 17,000 people from diverse backgrounds. Their mean BMI was 33, and nobody was less than BMI 27. They were divided into two similar groups. One was given semaglutide (Wegovy) and the other was given a placebo. As the trial progressed, Covid-19 struck. Both groups saw similar rates of infection. Among the 184 who died of Covid-19, 78 had been taking semaglutide and 106 were on placebo. The difference is significant enough to suggest that the drug helped save some lives. In the trial, some died of reasons other than the pandemic. After accounting for all causes of death, those taking the drug saw 19 per cent fewer fatalities. No, this does not mean that GLP-1 drugs can be a treatment for Covid-19. What it does show is that the drug is improving overall health through weight loss and reduced inflammation. It confirms what we know about obesity: It's a disease. Did some of those patients survive the pandemic only because weight loss improved their overall health, or also because the drug reduced their inflammation levels, or were there more reasons? This is an open question because scientists are still discovering the full range of what GLP-1 drugs do inside the body. Their action on various diseases could help understand the disease better, perhaps aiding the discovery of new specific drugs and treatments for those diseases. GLP-1 drugs themselves could, some day, be prescribed for many of those conditions. It is important to note that research is ongoing and incomplete. Patients should not self-medicate. Even if GLP-1 drugs are approved by the US FDA or other regulators for some of these conditions, they must be used only under medical supervision. Here are some medical conditions in which GLP-1 drugs have been found to be helpful so far. Heart disease In March 2024, the US FDA approved Wegovy (semaglutide, same as Ozempic) for patients who had heart disease along with obesity or were overweight even if they did not have diabetes. This followed a large trial called SELECT (the same trial that showed the Covid-19 effect fortuitously), which had 17,600 patients enrolled in two groups. In the placebo group, 8 per cent of participants saw major adverse cardiovascular events (MACEs), such as heart attack, stroke or cardiovascular death. In the group taking semaglutide, the incidence was 6.5 per cent. That's a nearly 20 per cent reduction in risk. While this trial used weekly injectable semaglutide, the more recent SOUL trial, involving almost 10,000 participants, used oral semaglutide (Rybelsus) and showed a reduction in MACE of 14 per cent. Statins remain the main drug for people with heart disease, but these results demonstrate the role of semaglutide in the prevention of heart disease on top of statin therapy. Tirzepatide (GIP + GLP-1) has also been shown to reduce cardiovascular risk. In an international trial of 713 adults in nine countries, including the US, called the SUMMIT trial, participants with heart failure taking tirzepatide for two years had significantly improved cardiovascular health and reduced progression of heart failure. An analysis of 13 GLP-1 drug trials comprising more than 80,000 patients showed significant reductions in MACE, overall and cardiovascular mortality, stroke, and need for coronary procedures like angioplasty and surgery, regardless of the presence of diabetes. The benefits could not be explained by weight loss alone. These trials have led to guidelines that all people with diabetes and/or obesity who either suffer from or are at risk of heart disease should be treated with GLP-1 drugs. However, since people with diabetes and/or obesity are at higher risk of heart attack and stroke anyway, it is prudent to consider the prescription of these drugs in most people with diabetes even if they have no evidence of heart disease. Chronic kidney disease In January 2025, the US FDA approved the use of semaglutide in patients who have both diabetes and kidney disease. Our kidneys filter out toxins from the body and pass them through the urine. Their ability to do so starts declining in patients with diabetes. The FLOW trial showed that for patients with both type 2 diabetes and chronic kidney disease, taking semaglutide lowered the risk of complications (dialysis, need for transplant) by 24 per cent. It also slowed down the decline of their kidney function. Moreover, in a post hoc analysis of the SURPASS-4 randomised clinical trial, tirzepatide decreased protein excretion, slowed decline in kidney function and reduced death due to kidney causes in patients with type 2 diabetes. Cancer Since obesity raises the risk of some types of cancer, it is not surprising that studies have started finding a reduced incidence of cancer among those taking GLP-1 drugs. This is similar to the reduced risk of cancer seen among those who have undergone bariatric surgery. Obesity-related cancers are concentrated around the metabolic organs and, among women, around the reproductive organs as well. An observational study of 1.65 million patients in the US found a reduced risk of ten types of obesity-related cancers among diabetes patients taking GLP-1 drugs as compared to those on insulin. Another study found the risk of 13 types of cancer reduced by 22 per cent in those who underwent bariatric surgery and by 39 per cent among those who took GLP-1 drugs. Excerpted with permission from The Weight Loss Revolution, Ambrish Mithal and Shivam Vij, Juggernaut.
New Indian Express
3 hours ago
- New Indian Express
Guntur GGH to offer free liver transplants
GUNTUR: Guntur Government General Hospital (GGH) is set to become the first government hospital in Andhra Pradesh to offer free liver transplantation surgeries to economically disadvantaged patients. The surgeries are expected to begin by October, while free knee replacement procedures will resume by mid-August after a prolonged interval. This initiative marks a significant milestone for public healthcare in the state. With the recent issuance of the Jeevandan AP Deceased Donor Certificate, GGH is now authorized to perform organ transplants using organs from deceased donors. Patients registered for liver transplants will be treated based on a waiting list to ensure transparency and fairness. Speaking to TNIE, GGH Superintendent Dr. SSV Ramana confirmed that the groundwork is nearly complete. 'Both knee and liver transplant surgeries will commence shortly, restoring access to life-saving treatment for patients unable to afford private care,' he said. To support this initiative, the hospital has set up two dedicated operation theaters at a cost of Rs.10 lakh and appointed three transplant coordinators. A team of specialists in general medicine, hepatology, anesthesia, and surgery has undergone intensive training under the guidance of Dr. Rajnikanth, a senior liver transplant expert from Chennai. GGH performs 22 kidney transplants Awareness campaigns have also been launched to promote organ donation, although only deceased donor transplants are currently permitted. GGH has a track record of performing complex surgeries, including a successful heart transplant in 2016, the first of its kind in a state-run facility. Since then, the hospital has performed 22 kidney transplants and several knee replacements. However, all transplant services were suspended during the COVID-19 pandemic and have not resumed until now. The liver transplant program, which was long in the pipeline, was delayed due to administrative and logistical hurdles. With approvals and infrastructure now in place, officials say the hospital is finally ready to offer this critical service to the underprivileged.
New Indian Express
3 hours ago
- New Indian Express
FMGs allege stalling of PRs despite Andhra Pradesh HC order
VIJAYAWADA: Foreign Medical Graduates (FMGs) in Andhra Pradesh have accused an officer in the Andhra Pradesh Medical Council (APMC) of deliberately stalling their permanent registrations (PRs) for over 14 months, despite a High Court ruling in their favour. Of the 1,500 FMGs in the State, about 500 who have completed internships claim that they fall under the 2002 guidelines, not the National Medical Commission's (NMC) 2021 regulations, which apply only to students enrolled after November 18, 2021. They allege the APMC is wrongly applying the 2021 rules, even though NMC regulations and a June 19, 2024, notice make no distinction for Andhra Pradesh students. The FMGs raised concerns after the NMC, in response to the State government's appeal, clarified that FMGs must compensate for online study through extended offline courses. The NMC said complying with the AP High Court order would arbitrarily relax norms and advised the State to file a review petition on August 7. The AP High Court has issued two verdicts on FMG internships, and the APMC has filed a review petition. Speaking to TNIE, Dr Bathini Jessy Manisha, a 2016-2022 graduate from Yerevan State Medical University, Armenia, said, 'The Registrar has been repeatedly claiming we studied online, but hides the fact that after a brief online period during Covid-19, we returned abroad to complete classes, clinicals and exams in offline mode. Worse, they are counting holiday periods as 'online study duration' to inflate the timeline and deny us registration. This is a calculated attempt, not a mistake.' Dr Manisha completed 56 months of offline study and four months online between March and September 2020. She finished her internship at Kurnool Medical College in November 2024. 'I come under the 2002 regulations. The court has recognised our eligibility. Every delay costs us opportunities, mental peace and dignity,' she said. FMGs claim the APMC has ignored explicit court orders to issue registrations, seeking extensions citing 'lack of clarity' just before compliance deadlines, which they see as a deliberate delay tactic.
